ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zeprumetostat

Also written as “SHR2554”, “TLN-254” and “SHR2554 Tablets”.

Its studies are mostly in Lymphoma · Neoplasms · Prostatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 2 companies.

Drug pageZeprumetostat: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 5, 202317 company-led studies, 7 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicineits history only166 open or runningphase 3since Nov 5, 2023Jul 10, 2018Apr 2027phase 2 · NCT06368167
Treeline Biosciences11 open or runningphase 1since Dec 10, 2024Dec 10, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Treeline Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2024Named zeprumetostatINNProposed as its International Nonproprietary Name in WHO's List 131 · before, SHR2554, TLN-254
  2. Dec 10, 2024First study: phase 1 study in LymphomaFirst studyNCT06733441 · 50 enrolled · United States, Canada

Ahead

  1. Nov 15, 2026Primary completion: phase 1 study in LymphomaNCT06733441

TargetBeta

EZH2 →read by rule
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), ”NCIt, by rule

Other programs on EZH2

ProgramCompanyFurthest phaseStudies
mevrometostatPfizerphase 37
TR115ruletarapeutics-science-incphase 33
tulmimetostatNovartisphase 23
EZH1/2 Inhibitor HH2853ruleHaihe Biopharmaphase 22
valemetostatruleDaiichi Sankyophase 11

Studies

The one study Treeline Biosciences leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06733441Lymphoma · United States, Canada1Active, not recruitingNov 15, 202650

How it is read

Names in the registry

  • “SHR2554”, 6 entries
  • “TLN-254”, 2 entries
  • “SHR2554 Tablets”, 2 entries
  • “SHR2554 Tablet”, 1 entry
  • “SHR2554; Chidamide analog tablets”, 1 entry

Codes read as this program: SHR2554.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.